SYNPO

Across TCGA pan-cancer cohorts, SYNPO Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated SYNPO data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SYNPO Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SYNPO expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

LIHC, UCEC, and MESO are the cancer types where SYNPO Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.040	0.553	<.001	18	view →
UCEC	OS	Median	All	0.957	0.652	.011	16	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
SKCM	OS	Median	All	0.179	0.781	<.001	9	view →
PRAD	DFS	Median	All	0.598	0.888	.001	6	view →
LGG	DFS	Median	All	0.110	0.833	<.001	6	view →
LUSC	OS	Median	All	0.081	0.818	<.001	6	view →
LUAD	OS	Median	All	0.035	0.788	<.001	6	view →
COAD	DFS	Median	All	0.904	0.677	.045	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

SYNPO–LIHC (DFS)

Open the LIHC breakdown →